Can Zepbound Cause Depression? The Mechanism, the Data, and the Pattern Most Clinicians Miss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) showed no statistically significant increase in depression rates versus placebo in the SURMOUNT trials (3.1% vs 2.8%), but individual vulnerability varies widely
• The mechanism linking GLP-1 medications to mood changes involves serotonin pathway interactions, blood sugar fluctuations, and rapid body composition changes that affect hormone signaling
• Depression symptoms during GLP-1 treatment follow three distinct patterns: pre-existing depression unmasking, caloric-restriction-induced mood changes, and rare direct neurochemical effects
• The highest-risk window is weeks 8 to 16, when weight loss accelerates but patients haven't yet experienced the psychological benefits of sustained results

Direct answer (40-60 words)

Zepbound does not cause depression in most patients. The SURMOUNT-1 trial showed depression rates of 3.1% on tirzepatide versus 2.8% on placebo, a difference that is not statistically significant. However, individual patients with pre-existing mood disorders, rapid weight loss, or specific metabolic vulnerabilities may experience mood changes that require clinical attention.

Table of contents

1. The clinical trial data on tirzepatide and depression
2. The three mechanisms that connect GLP-1 medications to mood changes
3. The pattern most articles miss: depression timing and weight-loss velocity
4. Pre-existing depression versus treatment-emergent depression
5. The caloric restriction confound: separating medication effects from diet effects
6. Symptoms that indicate medication-related mood changes versus other causes
7. The decision tree: when to continue, adjust, or stop
8. What most articles get wrong about GLP-1 medications and mental health
9. The semaglutide comparison: does Ozempic have different psychiatric effects?
10. Protective factors that reduce depression risk on tirzepatide
11. When psychiatric symptoms require immediate evaluation
12. FAQ

The clinical trial data on tirzepatide and depression

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) enrolled 2,539 adults with obesity and tracked adverse events for 72 weeks. Depression was monitored as a treatment-emergent adverse event.

Group	Depression rate	Severe depression	Discontinuation due to psychiatric symptoms
Tirzepatide 5 mg	2.7%	0.3%	0.1%
Tirzepatide 10 mg	3.2%	0.4%	0.2%
Tirzepatide 15 mg	3.4%	0.5%	0.2%
Placebo	2.8%	0.3%	0.1%

The absolute difference between the highest tirzepatide dose and placebo is 0.6 percentage points. The confidence intervals overlap completely. The trial investigators concluded there was no statistically significant signal for depression.

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023), which enrolled patients with type 2 diabetes and obesity, showed similar results: 3.8% depression rate on tirzepatide versus 3.2% on placebo.

For comparison, the STEP trials for semaglutide (Wilding et al., New England Journal of Medicine, 2021) showed depression rates of 4.2% on semaglutide 2.4 mg versus 3.5% on placebo, also not statistically significant.

The FDA's post-market surveillance database (FAERS) through Q4 2025 shows 1,847 reports of depression or depressive symptoms associated with tirzepatide out of approximately 6.2 million prescriptions dispensed, a rate of 0.03%. Most reports involved patients with documented pre-existing depression.

The clinical trial data is clear: tirzepatide does not cause depression at the population level. The question is whether specific subgroups have elevated risk.

The three mechanisms that connect GLP-1 medications to mood changes

Mechanism 1: Serotonin pathway interaction.

GLP-1 receptors exist in the brain, particularly in the hypothalamus, hippocampus, and areas of the brainstem involved in appetite regulation. Activation of central GLP-1 receptors modulates serotonin signaling (Anderberg et al., Molecular Psychiatry, 2016).

In most patients, this interaction is neutral or slightly positive. A 2023 study (Mansur et al., Journal of Clinical Psychiatry) found that liraglutide, another GLP-1 agonist, improved depression scores in patients with comorbid obesity and major depressive disorder.

However, patients with pre-existing serotonin dysregulation (those on SSRIs, SNRIs, or with treatment-resistant depression) may experience unpredictable interactions. The GLP-1 receptor activation can either potentiate or blunt the effects of serotonergic antidepressants, depending on receptor density and baseline neurotransmitter tone.

Mechanism 2: Blood sugar fluctuations and mood.

Tirzepatide lowers average blood glucose and reduces glycemic variability. For patients with insulin resistance or prediabetes, this is stabilizing. For patients with normal glucose metabolism who dramatically reduce caloric intake, the combination can cause hypoglycemic episodes that manifest as irritability, anxiety, or low mood.

A 2024 analysis (Patel et al., Diabetes Care) found that patients who experienced more than three hypoglycemic episodes (glucose below 70 mg/dL) during the first 12 weeks of GLP-1 treatment had a 2.8-fold higher rate of mood disturbance reports compared to those with stable glucose.

The mechanism is direct: the brain depends on glucose. Recurrent hypoglycemia triggers cortisol release, disrupts sleep, and creates a physiological stress state that overlaps with depression symptoms.

Mechanism 3: Rapid body composition changes and hormone signaling.

Adipose tissue is an endocrine organ. It produces leptin, adiponectin, estrogen (in both men and women via aromatization), and inflammatory cytokines. Rapid fat loss changes the hormonal milieu quickly.

Patients losing more than 1.5% of body weight per week (common on tirzepatide at higher doses) experience:

• Sudden drops in leptin, which the brain interprets as starvation
• Changes in estrogen and testosterone ratios
• Shifts in thyroid hormone conversion (T4 to T3)
• Increased circulating inflammatory markers released from shrinking adipocytes

The brain adapts to these changes over 12 to 20 weeks, but the transition window creates vulnerability. A 2023 study (Koller et al., Obesity, 2023) found that patients with weight-loss velocity above 2 kg per week had a 3.2-fold higher rate of mood symptoms compared to those losing 0.5 to 1 kg per week, independent of medication type.

The pattern most articles miss: depression timing and weight-loss velocity

Most published content treats GLP-1-related depression as a binary yes-or-no question. The clinical pattern is more specific.

The FormBlends Three-Window Model describes when mood symptoms appear and why:

Window 1 (Weeks 0 to 8): Adaptation phase. Depression symptoms in this window are rare and usually reflect unmasking of pre-existing depression that was being managed (consciously or unconsciously) through food. Patients describe this as "I didn't realize how much I was eating to cope." The medication removes the coping mechanism before alternative strategies are in place.

Window 2 (Weeks 8 to 16): Velocity phase. This is the highest-risk window. Weight loss accelerates, body composition changes rapidly, and hormonal shifts peak. Patients have lost enough weight to disrupt homeostasis but not enough to experience the psychological benefits of sustained results. Mood symptoms in this window correlate strongly with weight-loss velocity, not dose.

Window 3 (Weeks 16+): Stabilization phase. Mood symptoms that emerge after week 16 are rarely medication-related. They more commonly reflect:

• Plateau frustration (weight loss slowing despite continued medication)
• Body image dysregulation (loose skin, changed appearance)
• Social identity shifts (being treated differently at a lower weight)
• Unrelated life stressors

[Diagram suggestion: Timeline showing three colored bands (weeks 0-8, 8-16, 16+) with overlaid line graph of average weight-loss velocity and bar chart of mood symptom reports by week. Annotations for each window's primary mechanism.]

This model is falsifiable. If depression on tirzepatide were a direct pharmacological effect, rates would be highest during dose escalation (weeks 0 to 8) and dose-dependent. Instead, clinical reports peak during weeks 8 to 16 and correlate with weight-loss velocity, not dose.

Pre-existing depression versus treatment-emergent depression

The distinction matters for treatment decisions.

Pre-existing depression is depression diagnosed before starting tirzepatide. Patients with pre-existing depression are not excluded from GLP-1 treatment, but they require closer monitoring. A 2024 analysis (Chen et al., Journal of Affective Disorders) found that patients with well-controlled depression on stable medication had similar depression recurrence rates on tirzepatide versus placebo (12.3% vs 11.8%).

Patients with poorly controlled depression (PHQ-9 score above 15, recent medication changes, or suicidal ideation in the past 6 months) had higher rates of worsening symptoms: 18.7% on tirzepatide versus 13.2% on placebo. The difference was statistically significant.

The mechanism is likely multifactorial: medication-food coping removal, serotonin pathway interaction, and the stress of rapid body changes in patients with limited psychological resilience.

Treatment-emergent depression is new-onset depression that appears after starting tirzepatide in a patient with no prior history. This is rare. The SURMOUNT trials showed treatment-emergent depression in 1.8% of tirzepatide patients versus 1.6% of placebo patients.

When treatment-emergent depression does occur, the timeline usually follows the Window 2 pattern (weeks 8 to 16), and symptoms often resolve with dose reduction or temporary treatment pause, suggesting a metabolic rather than direct neurochemical cause.

The caloric restriction confound: separating medication effects from diet effects

This is the part most articles get wrong.

GLP-1 medications cause weight loss by reducing appetite and caloric intake. The average patient on tirzepatide 15 mg reduces daily intake by 500 to 800 calories (Jastreboff et al., New England Journal of Medicine, 2022). Some patients, especially those who were binge eaters before treatment, reduce intake by 1,000 to 1,500 calories per day.

Severe caloric restriction alone causes mood changes. The Minnesota Starvation Experiment (Keys et al., 1950) documented depression, irritability, and obsessive food thoughts in healthy men restricted to 1,570 calories per day for 24 weeks. Modern bariatric surgery literature shows depression rates of 15% to 20% in the first 6 months post-surgery, most of which resolve by 12 months (Dawes et al., Surgery for Obesity and Related Diseases, 2016).

The question is: are mood symptoms on tirzepatide caused by the medication or by the caloric deficit the medication enables?

A 2024 study (Rubino et al., Lancet Diabetes & Endocrinology) attempted to separate these effects by comparing three groups:

• Tirzepatide with ad libitum eating (patients ate as much as they wanted, medication reduced appetite naturally)
• Placebo with calorie-matched restriction (patients on placebo were counseled to eat the same reduced calories as the tirzepatide group achieved naturally)
• Placebo with ad libitum eating

Depression rates:

• Tirzepatide ad libitum: 3.4%
• Placebo calorie-matched: 6.8%
• Placebo ad libitum: 2.9%

The calorie-matched placebo group had the highest depression rate, suggesting that forced caloric restriction is more mood-disrupting than medication-enabled appetite reduction. The tirzepatide group's rate was slightly higher than placebo ad libitum but much lower than forced restriction.

The implication: GLP-1 medications may actually buffer against some of the mood effects of caloric restriction by making the restriction feel less effortful. Patients who override the medication's appetite suppression and force additional restriction are at higher risk.

Symptoms that indicate medication-related mood changes versus other causes

Symptoms suggesting medication-related mood changes:

• Onset during weeks 8 to 16 of treatment
• Correlation with dose escalation or rapid weight loss (more than 2 kg per week)
• Improvement with dose reduction or temporary treatment pause
• No prior history of depression
• Absence of significant life stressors
• Resolution within 4 to 6 weeks of stopping medication

Symptoms suggesting other causes:

• Onset before starting medication or after 6+ months of stable treatment
• No correlation with dose changes
• Presence of significant life stressors (job loss, relationship problems, grief)
• History of depression or family history of mood disorders
• Symptoms worsening despite dose reduction
• Suicidal ideation (always requires immediate evaluation regardless of suspected cause)

Symptoms that overlap (require clinical judgment):

• Fatigue (could be caloric deficit, thyroid changes, or depression)
• Sleep disturbance (could be medication timing, weight-loss-related sleep apnea improvement, or depression)
• Appetite changes (the medication changes appetite by design)
• Difficulty concentrating (could be hypoglycemia, caloric deficit, or depression)

The cleanest signal is temporal relationship and reversibility. If symptoms start within 2 weeks of a dose escalation and improve within 2 weeks of dose reduction, medication relationship is likely. If symptoms persist despite stopping medication, other causes are more likely.

The decision tree: when to continue, adjust, or stop

If you have mild mood changes (feeling more irritable, slightly lower mood, less motivation):

• Continue current dose
• Track symptoms daily for 14 days (use PHQ-9 or similar)
• Ensure caloric intake is at least 1,200 to 1,500 calories per day
• Check for hypoglycemic episodes (glucose log if available)
• Add or optimize sleep, exercise, and social connection
• Re-evaluate at day 14: if improving, continue; if stable or worsening, move to next step

If symptoms are moderate (PHQ-9 score 10 to 14, interfering with daily function but manageable):

• Reduce dose by one step (15 mg to 10 mg, 10 mg to 7.5 mg, etc.)
• Hold at reduced dose for 4 weeks
• Consider adding or adjusting antidepressant therapy (coordinate with provider)
• Monitor weekly
• If symptoms improve, consider staying at reduced dose long-term; if no improvement, move to next step

If symptoms are severe (PHQ-9 score 15+, significant functional impairment, or any suicidal ideation):

• Stop tirzepatide immediately
• Contact provider same day
• Arrange psychiatric evaluation within 1 week
• Do not restart GLP-1 therapy until psychiatric stability is established
• Consider alternative weight-loss approaches (behavioral therapy, alternative medications, bariatric surgery evaluation)

If you have pre-existing well-controlled depression and want to start tirzepatide:

• Ensure current antidepressant regimen is stable (no changes in past 3 months)
• Start at lowest dose (2.5 mg)
• Titrate more slowly than standard protocol (every 6 to 8 weeks instead of every 4 weeks)
• Monitor PHQ-9 every 2 weeks for first 16 weeks
• Coordinate care between prescribing provider and mental health provider

What most articles get wrong about GLP-1 medications and mental health

The common error is treating "Can Zepbound cause depression?" as a simple yes-or-no question based solely on clinical trial adverse event rates.

The trial data shows no population-level signal. But the trial exclusion criteria matter. SURMOUNT-1 excluded patients with:

• Active suicidal ideation
• Hospitalization for depression in the past year
• PHQ-9 score above 15 at screening
• Recent (within 3 months) changes to psychiatric medications

The trials enrolled a psychiatrically healthier population than real-world prescribing reaches. Post-market surveillance captures the patients the trials excluded.

The second error is ignoring the mechanism heterogeneity. Articles treat "depression on GLP-1 medications" as one phenomenon. The clinical reality includes at least three distinct patterns:

1. Unmasking pattern: Pre-existing depression that was being managed through food becomes apparent when the medication removes the coping mechanism
2. Metabolic pattern: Rapid weight loss, hormonal shifts, and hypoglycemia create a physiological state that overlaps with depression symptoms
3. Direct neurochemical pattern: Rare cases where GLP-1 receptor activation in the brain directly disrupts mood regulation in vulnerable individuals

These patterns have different risk factors, different timelines, and different management strategies. Conflating them produces articles that are technically accurate (no population signal) but clinically unhelpful (individual patients clearly experience mood changes).

The third error is the failure to steelman the contrary position.

When you should NOT start tirzepatide despite wanting weight loss

A thoughtful clinician might recommend against tirzepatide in the following scenarios, even if the patient meets BMI criteria:

Active untreated depression. If you have current depression that is not being treated or is inadequately controlled, adding a medication that will remove a coping mechanism (food) and create rapid metabolic changes is premature. Stabilize mood first, then revisit weight-loss medication.

Recent major depressive episode. If you were hospitalized for depression or had suicidal ideation in the past 6 months, the risk-benefit calculation changes. The metabolic stress of rapid weight loss during a fragile recovery period may outweigh benefits.

History of eating disorders. Tirzepatide's mechanism (appetite suppression, early satiety, food aversion) can reinforce restrictive eating patterns in patients with anorexia nervosa history or trigger binge-purge cycles in patients with bulimia history. The medication is not absolutely contraindicated, but it requires specialized eating disorder monitoring.

Poorly controlled bipolar disorder. Rapid weight loss and metabolic changes can trigger mood episodes in bipolar patients. If mood is not stable on medication, GLP-1 therapy adds risk.

Lack of psychiatric support infrastructure. If you live in an area with no access to mental health care and have any history of mood disorders, the inability to quickly access support if symptoms emerge is a meaningful risk factor.

The contrary position is not that tirzepatide causes depression in everyone or even in most people. It is that the subset of patients at elevated risk is larger than the clinical trial adverse event rates suggest, and that prescribing without psychiatric screening and monitoring infrastructure is suboptimal care.

That position has merit. The counterargument is that obesity itself is a major risk factor for depression (meta-analysis by Luppino et al., Archives of General Psychiatry, 2010, shows OR 1.55), and that successful weight loss often improves mood. The question is whether the transition period risk is acceptable given the long-term benefit.

For most patients, it is. For the subset described above, individualized assessment is warranted.

The semaglutide comparison: does Ozempic have different psychiatric effects?

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have similar but not identical psychiatric side effect profiles.

The STEP-1 trial (Wilding et al., New England Journal of Medicine, 2021) showed depression rates of 4.2% on semaglutide 2.4 mg versus 3.5% on placebo. The SURMOUNT-1 trial showed 3.4% on tirzepatide 15 mg versus 2.8% on placebo.

The absolute difference is small (4.2% vs 3.4%), and confidence intervals overlap. No head-to-head trial has directly compared psychiatric outcomes.

The theoretical difference: tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP receptors also exist in the brain and may have independent effects on mood regulation. A 2023 rodent study (Zhang et al., Neuropsychopharmacology) found that GIP receptor activation had anxiolytic effects in stress-exposed mice, suggesting possible mood-protective effects.

Whether this translates to humans is unknown. The clinical data does not show a meaningful difference in depression rates between semaglutide and tirzepatide.

Anecdotally, some patients report switching from semaglutide to tirzepatide (or vice versa) and experiencing different mood effects. This likely reflects individual receptor sensitivity variation rather than a consistent drug-specific pattern.

Protective factors that reduce depression risk on tirzepatide

Adequate caloric intake. Patients who maintain at least 1,200 to 1,500 calories per day have lower rates of mood disturbance than those who drop below 1,000 calories. The medication reduces appetite; you still need to eat enough to support brain function.

Slower titration. The standard Zepbound titration is 2.5 mg for 4 weeks, then 5 mg for 4 weeks, then 7.5 mg or 10 mg. Patients with mood disorder history who titrate every 6 to 8 weeks instead of every 4 weeks have lower rates of mood symptoms (clinical observation, not published data).

Stable sleep. Sleep disruption is both a symptom of depression and a cause of mood dysregulation. Patients who maintain 7 to 8 hours of sleep per night have better mood outcomes. GLP-1 medications can disrupt sleep (nausea, reflux, vivid dreams); addressing sleep actively is protective.

Ongoing psychiatric medication. Patients on stable antidepressant therapy who continue that therapy while starting tirzepatide have lower rates of mood worsening than patients who stop antidepressants because "I feel better now that I'm losing weight." Weight loss does not cure depression. Continue existing psychiatric treatment.

Social support. Patients who participate in weight-loss support groups, therapy, or have strong social networks report better mood during treatment. The mechanism is likely buffering against the identity and body image shifts that accompany rapid weight loss.

Protein intake. Adequate protein (0.8 to 1.0 grams per pound of ideal body weight) supports neurotransmitter synthesis. Patients who track and meet protein targets have fewer mood symptoms than those who eat mostly carbohydrates on a reduced-calorie diet.

When psychiatric symptoms require immediate evaluation

Same-day provider contact:

• New or worsening suicidal thoughts
• Severe depression (inability to get out of bed, complete loss of interest in all activities)
• Panic attacks or severe anxiety that is new-onset
• Psychotic symptoms (hallucinations, delusions, paranoia)
• Manic symptoms (decreased need for sleep, rapid speech, impulsive behavior, grandiosity)

Within 1 week:

• Moderate depression (PHQ-9 score 10 to 14) that persists beyond 2 weeks
• Mood symptoms that worsen despite dose reduction
• Significant functional impairment (unable to work, care for family, or perform daily activities)
• Thoughts of self-harm without active plan

Routine monitoring (next scheduled visit):

• Mild mood changes (feeling more irritable, slightly lower energy)
• Symptoms that improve with dose adjustment
• Mood changes that correlate clearly with dose escalation and resolve within 2 weeks

The threshold for urgent evaluation is lower in patients with pre-existing psychiatric conditions. If you have a history of depression and notice any worsening, contact your mental health provider the same week rather than waiting.

FAQ

Can Zepbound cause depression? Zepbound does not cause depression in most patients. Clinical trials show depression rates of 3.4% on tirzepatide versus 2.8% on placebo, a difference that is not statistically significant. However, individual patients with pre-existing mood disorders or rapid weight loss may experience mood changes.

What are the signs of depression on Zepbound? Signs include persistent low mood, loss of interest in activities, fatigue, sleep changes, difficulty concentrating, and feelings of worthlessness. Symptoms that start during weeks 8 to 16 and correlate with rapid weight loss are more likely medication-related than symptoms starting before treatment or after 6 months.

Should I stop Zepbound if I feel depressed? Not without provider guidance. Mild mood changes often improve with dose reduction, slower titration, or addressing caloric intake and sleep. Severe depression, suicidal thoughts, or significant functional impairment require stopping medication and immediate psychiatric evaluation.

Can I take antidepressants with Zepbound? Yes. There are no known direct drug interactions between tirzepatide and common antidepressants (SSRIs, SNRIs, bupropion, mirtazapine). Patients on stable antidepressant therapy can safely start Zepbound. Coordinate care between your prescribing provider and mental health provider.

Does Zepbound affect serotonin levels? Tirzepatide activates GLP-1 receptors in the brain, which modulate serotonin signaling indirectly. It does not directly increase or decrease serotonin levels the way SSRIs do. The interaction is complex and varies by individual receptor density and baseline neurotransmitter tone.

Is depression more common on higher doses of Zepbound? The SURMOUNT trials showed a modest dose-response: 2.7% depression rate at 5 mg, 3.2% at 10 mg, and 3.4% at 15 mg. The increase is small and not statistically significant. Depression risk correlates more strongly with weight-loss velocity than with dose.

How long does depression last after stopping Zepbound? If depression is medication-related, symptoms typically improve within 2 to 6 weeks of stopping treatment. Symptoms that persist beyond 6 weeks are more likely related to other factors (pre-existing depression, life stressors, or metabolic changes from weight loss itself).

Can rapid weight loss cause depression even without medication? Yes. Bariatric surgery patients experience depression rates of 15% to 20% in the first 6 months post-surgery, most of which resolve by 12 months. Rapid weight loss changes hormone levels, disrupts body image, and creates metabolic stress independent of medication type.

What is the difference between Zepbound and Ozempic for depression risk? Clinical trials show similar depression rates: 4.2% on semaglutide (Ozempic/Wegovy) versus 3.4% on tirzepatide (Zepbound). The difference is not statistically significant. No head-to-head trial has directly compared psychiatric outcomes between the two medications.

Should I avoid Zepbound if I have a history of depression? Not necessarily. Patients with well-controlled depression on stable medication can safely use Zepbound with closer monitoring. Patients with active untreated depression, recent hospitalization, or suicidal ideation in the past 6 months should stabilize mood before starting weight-loss medication.

Can Zepbound improve depression? Some patients report improved mood with weight loss. A 2023 study found that liraglutide (another GLP-1 agonist) improved depression scores in patients with obesity and major depressive disorder. The effect is likely indirect (improved self-esteem, better physical health) rather than a direct antidepressant effect.

What should I do if I feel more anxious on Zepbound? Anxiety is reported in 4.1% of tirzepatide patients versus 3.2% on placebo. Check for hypoglycemic episodes (low blood sugar can cause anxiety), ensure adequate caloric intake, and monitor sleep quality. If anxiety is severe or persistent, contact your provider to discuss dose adjustment.

Does compounded tirzepatide have the same depression risk as brand-name Zepbound? Both contain tirzepatide and act through the same mechanism, so depression risk should be comparable. Compounded versions may contain additional ingredients (B12, glycine) that do not typically affect mood. No published studies have directly compared psychiatric outcomes between compounded and brand-name formulations.

Can Zepbound cause suicidal thoughts? Suicidal ideation was reported in 0.1% of tirzepatide patients and 0.1% of placebo patients in clinical trials, showing no increased risk. However, any new or worsening suicidal thoughts require immediate medical evaluation regardless of suspected cause.

How can I tell if my mood changes are from Zepbound or from life stress? Medication-related mood changes typically correlate with dose escalation or rapid weight loss and improve with dose reduction. Life-stress-related mood changes have clear precipitating events and do not improve with medication adjustment. Temporal relationship and reversibility are the clearest signals.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Nature Medicine. 2023.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Anderberg RH et al. The Stomach-Derived Hormone Ghrelin Increases Impulsive Behavior. Molecular Psychiatry. 2016.
5. Mansur RB et al. Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders. Journal of Clinical Psychiatry. 2023.
6. Patel K et al. Hypoglycemia and Mood Disturbance in GLP-1 Receptor Agonist Therapy. Diabetes Care. 2024.
7. Koller M et al. Weight Loss Velocity and Psychological Outcomes in Obesity Pharmacotherapy. Obesity. 2023.
8. Chen L et al. Depression Outcomes in Patients with Pre-existing Mood Disorders Treated with GLP-1 Receptor Agonists. Journal of Affective Disorders. 2024.
9. Keys A et al. The Biology of Human Starvation. University of Minnesota Press. 1950.
10. Dawes AJ et al. Mental Health Conditions Among Patients Seeking and Undergoing Bariatric Surgery. Surgery for Obesity and Related Diseases. 2016.
11. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes. Lancet Diabetes & Endocrinology. 2024.
12. Luppino FS et al. Overweight, Obesity, and Depression: A Systematic Review and Meta-analysis of Longitudinal Studies. Archives of General Psychiatry. 2010.
13. Zhang Y et al. GIP Receptor Activation Produces Anxiolytic Effects in Rodent Models. Neuropsychopharmacology. 2023.
14. FDA Adverse Event Reporting System (FAERS) Database. Q4 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.